Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5257682 | 0.87 | POLB (0.61) | POLBMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL5261825 | 0.84 | POLB (0.64) | POLBMEN1KMT2AALDH1A1GAA | |
| SCHEMBL5259556 | 0.83 | MEN1 (0.56) | POLBMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL5256254 | 0.81 | POLB (0.57) | POLBMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL5255667 | 0.79 | MEN1 (0.56) | POLBMEN1KMT2AALDH1A1GAA | |
| SCHEMBL5261688 | 0.79 | POLB (0.51) | POLBMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL14531958 | 0.76 | ALDH1A1 (0.58) | POLBMEN1KMT2AALDH1A1GAA | |
| SCHEMBL5261504 | 0.75 | CCR3 (0.55) | POLBMEN1KMT2ACYP2D6ACKR3 | |
| SCHEMBL5258383 | 0.74 | MEN1 (0.51) | POLBMEN1KMT2ACYP2D6ACKR3 | |
| SCHEMBL5258034 | 0.73 | MEN1 (0.48) | POLBMEN1KMT2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1496896-A4 | INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2007-10-31 | — | — | EP | claimed |
| US-7223738-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-05-29 | — | — | US | claimed |
| US-20050222155-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2005-10-06 | — | — | US | claimed |
| EP-1496896-A1 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2005-01-19 | — | — | EP | claimed |
| WO-2003086394-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | claimed |
| EP-1496896-A4 | INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2007-10-31 | — | — | EP | disclosed |
| US-7223738-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050222155-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2005-10-06 | — | — | US | disclosed |
| EP-1496896-A1 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003086394-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222155-A1 | Inhibitors of akt activity | AKT1, AKT2, AKT3 | POLB 2450/4885MEN1 2983/4885KMT2A 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.